Drugs / MenACWY-CRM Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT00262028 | Apr 2005 → Nov 2006 | meningococcemia | Novartis Vaccines | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01466387 Comparator | Nov 2011 → Apr 2012 | Japanese encephalitis, meningococcal meningitis, rabies, typhoid fever +1 | Novartis | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MenACWY-CRM Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00262028 ↗ |
| Known as | MenACWY-CRM | “quadrivalent meningococcal glycoconjugate ACWY-CRM vaccine (MenACWY-CRM)” PMID 25308927 ↗ Oct 2014 |
| Modality | Vaccine | “MenACWY-CRM Vaccine” NCT00262028 ↗ |